An observational study in DLBCL - Diffuse Large B Cell Lymphoma, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Active, not recruiting at 9 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-29.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational
Study designobservational, non-interventional, retrospective, multicenter study.
The study focusing on information about the effectiveness and safety of polatuzumab vedotin plus rituximab (± bendamustine) in patients who received at least one dose of polatuzumab vedotin plus rituximab (± bendamustine) under the NPP (D.M. 7 Sep 2017) programme in the period between June 2019 and Feb 2020 in Italy.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's enrollment of 100 is below the median of 136 across 625 observational studies indexed under Lymphoma.
Browse Lymphoma studies →IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 493 studies on the registry; 273 are open to participants now.
Counted across the registry records on this site, refreshed daily.
DLBCL patients who received at least one dose of polatuzumab vedotin plus rituximab (± bendamustine) under the NPP (D.M. 7 Sep 2017) programme in the period between June 2019 and Feb 2020 in Italy.
Exclusion Criteria:
Patients with DLBCL treated with polatuzumab vedotin plus rituximab (± bendamustine) within a clinical trial context
overall response rate (ORR)
Effectiveness of polatuzumab vedotin plus rituximab (± bendamustine) in patients with relapsed or refractory DLBCL who have received at least one dose of polatuzumab vedotin plus rituximab (± bendamustine) under the NPP (D.M. 7 Sep 2017) in the period between June 2019 and Feb 2020 in Italy. This value is calculated as the sum of partial (PRR) and complete response rates (CRR) at end of treatment.
Time frame: through study completion, an average of 2 years
Overall Survival (OS)
is the length of time from either the date of diagnosis or the start of treatment ...
Time frame: through study completion, an average of 2 years
Progression Free Survival (PFS)
the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease
Time frame: through study completion, an average of 2 years
disease free survival (DFS) at 6 months
the time from random assignment to cancer recurrence or death from any cause.
Time frame: through study completion, an average of 2 years
frequency distribution of the causes of death
frequency
Time frame: through study completion, an average of 2 years
Mean treatment duration
Mean treatment duration
Time frame: through study completion, an average of 2 years
Incidence and type of adverse events and severe adverse events
Incidence
Time frame: through study completion, an average of 2 years
Proportion of patients with clinical disease progression
Proportion
Time frame: through study completion, an average of 2 years
Proportion of patients requiring one or more emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions
Proportion of patients with clinical disease progression
Time frame: through study completion, an average of 2 years
Best response rate (BRR)
Best response rate (BRR)
Time frame: through study completion, an average of 2 years
frequency distribution of the causes of treatment discontinuation
frequency distribution of the causes of treatment discontinuation
Time frame: through study completion, an average of 2 years
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna